8-K Announcements
6Material company update
Apr 9, 2026·SEC
Material company update
Mar 16, 2026·SEC
Material company update
Jan 7, 2026·SEC
FibroGen, Inc.(FGEN)Earnings, Financials & Key Ratios
FGEN•NASDAQ
$7.50
$585M mkt cap·Price updated Apr 24, 2026
AboutFibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Show more
- Revenue$30M-36.7%
- EBITDA-$148M+52.8%
- Net Income-$48M+83.3%
- EPS (Diluted)-0.48+83.6%
- Gross Margin47.47%-48.1%
- EBITDA Margin-498.71%+25.4%
- Operating Margin-507.8%+26.4%
- Net Margin-160.63%+73.6%
- Interest Coverage-18.24+54.3%
FGEN Key Insights
FibroGen, Inc. (FGEN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Sales declining 35.1% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
FGEN Price & Volume
FibroGen, Inc. (FGEN) stock price & volume — 10-year historical chart
Loading chart...
FGEN Growth Metrics
FibroGen, Inc. (FGEN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-14.24%
5 Years-35.07%
3 Years-49.88%
TTM-218.29%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM277.07%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM678.32%
Return on Capital
10 Years-44.09%
5 Years-73.3%
3 Years-97.28%
Last Year-104.79%
FGEN Recent Earnings
FibroGen, Inc. (FGEN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 8/12 qtrs (67%)
Q4 2025Latest
Nov 10, 2025EPS
$1.61
Est $4.01
+59.9%
Revenue
$1M
Est $2M
-35.6%
Q3 2025
Aug 11, 2025EPS
$3.38
Est $2.25
-50.2%
Revenue
$1M
Est $3M
-53.5%
Q2 2025
May 12, 2025EPS
$4.00
Est $0.75
-633.3%
Revenue
$3M
Est $2M
+37.0%
Q2 2025
Mar 17, 2025EPS
$0.08
Est $0.08
+0.0%
Revenue
$123M
Est $25M
-594.8%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 10, 2025 | $1.61vs $4.01+59.9% | $1Mvs $2M-35.6% |
| Q3 2025 | Aug 11, 2025 | $3.38vs $2.25-50.2% | $1Mvs $3M-53.5% |
| Q2 2025 | May 12, 2025 | $4.00vs $0.75-633.3% | $3Mvs $2M+37.0% |
| Q2 2025 | Mar 17, 2025 | $0.08vs $0.08+0.0% | $123Mvs $25M-594.8% |
Based on last 12 quarters of dataView full earnings history →
FGEN Peer Comparison
FibroGen, Inc. (FGEN) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AKBA | 392.83M | 1.48 | -74 | 47.46% | -2.26% | -16.39% | ||
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% | |||
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 INSM | 29.14B | 137.09 | -21.35 | 66.73% | -264.83% | -125.2% | 0.06 | |
 ARWR | 11.08B | 79.14 | -6486.89 | 232.58% | 18.54% | 35.64% | 0.73 | |
 GILD | 169.83B | 136.30 | 358.68 | 6.04% | 28.9% | 37.62% | 1.39 | |
 BMRN | 10.5B | 54.60 | 30.33 | 12.87% | 8.29% | 4.41% | 0.11 |
Compare FGEN vs Peers
FibroGen, Inc. (FGEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FGEN Income Statement
FibroGen, Inc. (FGEN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 179.58M | 125.67M | 212.96M | 256.58M | 176.32M | 235.31M | 140.73M | 46.8M | 29.62M | -118.09M |
| Revenue Growth % | -0.69% | -30.02% | 69.46% | 20.48% | -31.28% | 33.46% | -40.19% | -66.74% | -36.71% | -218.29% |
| Cost of Goods Sold | 187.21M | 196.52M | 235.84M | 1.15M | 8.87M | 449.19M | 20.28M | 3.96M | 15.56M | -20.39M |
| COGS % of Revenue | 104.25% | 156.38% | 110.74% | 0.45% | 5.03% | 190.89% | 14.41% | 8.47% | 52.53% | - |
| Gross Profit | -7.63M▲ 0% | -70.85M▼ 828.7% | -22.88M▲ 67.7% | 255.43M▲ 1216.3% | 167.45M▼ 34.4% | -213.88M▼ 227.7% | 120.45M▲ 156.3% | 42.84M▼ 64.4% | 14.06M▼ 67.2% | -97.71M▲ 0% |
| Gross Margin % | -4.25% | -56.38% | -10.74% | 99.55% | 94.97% | -90.89% | 85.59% | 91.53% | 47.47% | - |
| Gross Profit Growth % | 77.06% | -828.68% | 67.7% | 1216.34% | -34.44% | -227.73% | 156.32% | -64.43% | -67.18% | - |
| Operating Expenses | 233.23M | 248.28M | 299.65M | 344.74M | 359.33M | 74.65M | 421.48M | 365.56M | 164.48M | 26.33M |
| OpEx % of Revenue | 129.88% | 197.57% | 140.71% | 134.36% | 203.8% | 31.72% | 299.49% | 781.07% | 555.27% | - |
| Selling, General & Admin | 46.02M | 51.76M | 63.81M | 135.48M | 106.41M | 0 | 124.69M | 86.48M | 49.33M | 7.14M |
| SG&A % of Revenue | 25.63% | 41.19% | 29.96% | 52.8% | 60.35% | - | 88.6% | 184.78% | 166.54% | - |
| Research & Development | 187.21M | 196.52M | 235.84M | 209.26M | 252.92M | 387.04M | 296.79M | 266.47M | 95.69M | 17.73M |
| R&D % of Revenue | 104.25% | 156.38% | 110.74% | 81.56% | 143.45% | 164.48% | 210.89% | 569.35% | 323.05% | - |
| Other Operating Expenses | 0 | 0 | 42.16M | 0 | 0 | -312.4M | 0 | 12.61M | 19.45M | 1.46M |
| Operating Income | -53.65M▲ 0% | -122.61M▼ 128.5% | -86.69M▲ 29.3% | -89.31M▼ 3.0% | -191.88M▼ 114.8% | -288.53M▼ 50.4% | -301.02M▼ 4.3% | -322.72M▼ 7.2% | -150.42M▲ 53.4% | -124.04M▲ 0% |
| Operating Margin % | -29.88% | -97.57% | -40.71% | -34.81% | -108.83% | -122.62% | -213.9% | -689.53% | -507.8% | - |
| Operating Income Growth % | 30.88% | -128.52% | 29.29% | -3.02% | -114.84% | -50.37% | -4.33% | -7.21% | 53.39% | - |
| EBITDA | -47.61M | -116.51M | -80.13M | -67.86M | -169.83M | -273.72M | -290.42M | -312.79M | -147.72M | -122.95M |
| EBITDA Margin % | -26.51% | -92.71% | -37.63% | -26.45% | -96.32% | -116.32% | -206.36% | -668.31% | -498.71% | - |
| EBITDA Growth % | 33.82% | -144.7% | 31.22% | 15.31% | -150.27% | -61.17% | -6.1% | -7.7% | 52.77% | 24.27% |
| D&A (Non-Cash Add-back) | 6.04M | 6.1M | 6.56M | 21.45M | 22.05M | 14.81M | 10.6M | 9.93M | 2.69M | 1.09M |
| EBIT | -51.03M | -110.85M | -75.13M | -73.77M | -186.33M | -348.53M | -293.43M | -315.13M | -145.12M | -128.79M |
| Net Interest Income | -8.1M | -3.27M | 577K | 12.67M | 3.15M | -1.07M | 6.16M | -501K | -2.95M | -5.45M |
| Interest Income | 2.63M | 6.43M | 11.57M | 15.55M | 5.55M | - | 7.6M | 7.59M | 5.3M | 903K |
| Interest Expense | 10.72M | 9.71M | 10.99M | 2.88M | 2.4M | 1.07M | 1.44M | 8.1M | 8.25M | 6.35M |
| Other Income/Expense | -8.1M | -3.27M | 577K | 12.67M | 2.95M | -1.15M | 7.73M | -501K | -2.95M | -7.24M |
| Pretax Income | -61.75M▲ 0% | -125.88M▼ 103.9% | -86.12M▲ 31.6% | -76.64M▲ 11.0% | -188.93M▼ 146.5% | -289.68M▼ 53.3% | -293.3M▼ 1.2% | -323.22M▼ 10.2% | -153.37M▲ 52.6% | -131.27M▲ 0% |
| Pretax Margin % | -34.39% | -100.17% | -40.44% | -29.87% | -107.15% | -123.1% | -208.4% | -690.6% | -517.76% | 111.16% |
| Income Tax | -71K | 321K | 304K | 328K | 360K | 347K | 358K | -252K | -269K | -142K |
| Effective Tax Rate % | 0.11% | -0.26% | -0.35% | -0.43% | -0.19% | -0.12% | -0.12% | 0.08% | 0.18% | 0.11% |
| Net Income | -61.68M▲ 0% | -126.2M▼ 104.6% | -86.42M▲ 31.5% | -76.97M▲ 10.9% | -189.29M▼ 145.9% | -290.02M▼ 53.2% | -293.65M▼ 1.3% | -284.23M▲ 3.2% | -47.58M▲ 83.3% | 215.65M▲ 0% |
| Net Margin % | -34.35% | -100.43% | -40.58% | -30% | -107.36% | -123.25% | -208.66% | -607.29% | -160.63% | - |
| Net Income Growth % | 28.09% | -104.61% | 31.52% | 10.94% | -145.93% | -53.22% | -1.25% | 3.21% | 83.26% | 277.07% |
| Net Income (Continuing) | -61.68M | -120.88M | -86.42M | -76.97M | -189.29M | -290.02M | -293.65M | -322.97M | -153.1M | -131.13M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 38.74M | 105.52M | 3M |
| Minority Interest | 19.27M | 19.27M | 19.27M | 19.27M | 19.27M | 19.97M | 19.97M | 41.97M | 41.97M | 34.51M |
| EPS (Diluted) | -0.98▲ 0% | -1.73▼ 76.5% | -1.03▲ 40.5% | -0.89▲ 13.6% | -2.11▼ 137.1% | -3.15▼ 49.3% | -3.15▲ 0.0% | -2.92▲ 7.3% | -0.48▲ 83.6% | 53.33▲ 0% |
| EPS Growth % | 30.99% | -76.53% | 40.46% | 13.59% | -137.08% | -49.29% | 0% | 7.3% | 83.56% | 678.32% |
| EPS (Basic) | -0.98 | -1.73 | -1.03 | -0.89 | -2.11 | -3.15 | -3.15 | -2.92 | -0.48 | - |
| Diluted Shares Outstanding | 62.74M | 72.99M | 84.06M | 86.63M | 89.85M | 92.35M | 93.58M | 97.3M | 100.04M | 4.04M |
| Basic Shares Outstanding | 62.74M | 72.99M | 84.06M | 86.63M | 89.85M | 92.35M | 93.58M | 97.3M | 100.04M | 4.04M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
FGEN Balance Sheet
FibroGen, Inc. (FGEN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 266.52M | 748.97M | 690.01M | 702.49M | 755.11M | 474.06M | 492.83M | 331.56M | 196.51M | 133.42M |
| Cash & Short-Term Investments | 253.18M | 735.72M | 621.4M | 533.76M | 686.54M | 405.19M | 422.01M | 235.59M | 50.48M | 117.97M |
| Cash Only | 173.78M | 673.66M | 89.26M | 126.27M | 678.39M | 171.22M | 155.7M | 113.69M | 50.48M | 117.97M |
| Short-Term Investments | 79.4M | 62.06M | 532.14M | 407.49M | 8.14M | 233.97M | 266.31M | 121.9M | 0 | 0 |
| Accounts Receivable | 10.45M | 8.45M | 63.68M | 153.66M | 41.88M | 25.4M | 16.3M | 41.05M | 481K | 121K |
| Days Sales Outstanding | 21.24 | 24.55 | 109.15 | 218.6 | 86.7 | 39.4 | 42.27 | 320.16 | 5.93 | -0.68 |
| Inventory | 0 | 0 | 0 | 6.89M | 16.53M | 31.02M | 40.44M | 41.56M | 3.15M | 3.86M |
| Days Inventory Outstanding | - | - | - | 2.19K | 680.29 | 25.2 | 727.77 | 3.83K | 74 | -62.83 |
| Other Current Assets | 2.89M | 4.8M | 4.93M | 1.72M | 1.81M | 5.07M | 4.35M | 6.71M | 140.49M | 0 |
| Total Non-Current Assets | 203.04M | 149.68M | 190.58M | 154.91M | 71.73M | 299.76M | 117.26M | 91.97M | 18.02M | 3.59M |
| Property, Plant & Equipment | 123.66M | 129.48M | 127.2M | 82.34M | 63.25M | 119.39M | 100.5M | 81.37M | 97K | 0 |
| Fixed Asset Turnover | 1.45x | 0.97x | 1.67x | 3.12x | 2.79x | 1.97x | 1.40x | 0.58x | 305.37x | -4869.81x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 71.01M | 10.51M | 55.82M | 61.12M | 2.97M | 171.62M | 9.41M | 5.29M | 0 | 3.04M |
| Other Non-Current Assets | 8.37M | 9.7M | 7.57M | 11.44M | 5.5M | 8.75M | 7.35M | 5.31M | 17.92M | 50.89M |
| Total Assets | 469.55M▲ 0% | 898.65M▲ 91.4% | 880.6M▼ 2.0% | 857.4M▼ 2.6% | 826.84M▼ 3.6% | 773.82M▼ 6.4% | 610.09M▼ 21.2% | 423.53M▼ 30.6% | 214.53M▼ 49.3% | 137.01M▲ 0% |
| Asset Turnover | 0.38x | 0.14x | 0.24x | 0.30x | 0.21x | 0.30x | 0.23x | 0.11x | 0.14x | -0.68x |
| Asset Growth % | -0.22% | 91.38% | -2.01% | -2.63% | -3.56% | -6.41% | -21.16% | -30.58% | -49.35% | -191.65% |
| Total Current Liabilities | 65.13M | 77.26M | 89.03M | 102.75M | 163.19M | 225.5M | 273.56M | 217.67M | 133.31M | 35.97M |
| Accounts Payable | 6.22M | 5.51M | 9.14M | 6.09M | 24.79M | 26.1M | 30.76M | 17.96M | 5.06M | 5.09M |
| Days Payables Outstanding | 12.13 | 10.23 | 14.14 | 1.94K | 1.02K | 21.21 | 553.58 | 1.65K | 118.78 | -124.95 |
| Short-Term Debt | 0 | 0 | 0 | 983K | 0 | 0 | 0 | 40K | 0 | 0 |
| Deferred Revenue (Current) | 7.99M | 7.97M | 13.77M | 490K | 6.55M | 19.03M | 12.74M | 12.74M | 0 | 49.82M |
| Other Current Liabilities | 36.68M | 17.38M | 44.69M | 63.05M | 95.53M | 4.91M | 7.25M | 152.58M | 115.23M | 5.1M |
| Current Ratio | 4.09x | 9.69x | 7.75x | 6.84x | 4.63x | 2.10x | 1.80x | 1.52x | 1.47x | 1.47x |
| Quick Ratio | 4.09x | 9.69x | 7.75x | 6.77x | 4.53x | 1.96x | 1.65x | 1.33x | 1.45x | 1.45x |
| Cash Conversion Cycle | - | - | - | 472.86 | -253.19 | 43.4 | 216.46 | 2.49K | -38.85 | 61.44 |
| Total Non-Current Liabilities | 229.32M | 238.94M | 263.1M | 219.25M | 222.2M | 319.21M | 338M | 368.06M | 264.85M | 83.56M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 89.7M | 90.1M | 19.47M |
| Capital Lease Obligations | 97.35M | 97.76M | 97.16M | 38.55M | 26.24M | 88.78M | 79.59M | 66.64M | 70K | 70K |
| Deferred Tax Liabilities | 4.21M | 3.66M | 3.04M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 25.26M | 167.19M | 29.83M | 81.25M | 57.49M | 43.63M | 72.69M | 54.17M | 174.68M | 397.72M |
| Total Liabilities | 294.44M | 316.2M | 352.13M | 321.99M | 385.39M | 544.71M | 611.57M | 585.73M | 398.16M | 119.53M |
| Total Debt | 97.35M | 97.76M | 97.16M | 51.89M | 39.76M | 99.72M | 89.89M | 170.46M | 90.17M | 19.47M |
| Net Debt | -76.43M | -575.89M | 7.9M | -74.38M | -638.63M | -71.5M | -65.81M | 56.77M | 39.69M | -98.5M |
| Debt / Equity | 0.56x | 0.17x | 0.18x | 0.10x | 0.09x | 0.44x | - | - | - | 1.11x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.16x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.80x |
| Interest Coverage | -5.00x | -12.63x | -7.89x | -31.05x | -79.88x | -268.40x | -209.05x | -39.87x | -18.24x | -20.28x |
| Total Equity | 175.11M▲ 0% | 582.45M▲ 232.6% | 528.47M▼ 9.3% | 535.41M▲ 1.3% | 441.45M▼ 17.5% | 229.11M▼ 48.1% | -1.48M▼ 100.6% | -162.2M▼ 10859.4% | -183.63M▼ 13.2% | 17.48M▲ 0% |
| Equity Growth % | -11.03% | 232.62% | -9.27% | 1.31% | -17.55% | -48.1% | -100.65% | -10859.39% | -13.22% | 106.39% |
| Book Value per Share | 2.79 | 7.98 | 6.29 | 6.18 | 4.91 | 2.48 | -0.02 | -1.67 | -1.84 | 4.32 |
| Total Shareholders' Equity | 155.84M | 563.18M | 509.2M | 516.13M | 422.18M | 209.15M | -21.45M | -204.17M | -225.6M | -17.03M |
| Common Stock | 637K | 825K | 854K | 877K | 914K | 929K | 942K | 988K | 1.01M | -17.03M |
| Retained Earnings | -469.74M | -595.95M | -715.83M | -784.72M | -974.01M | -1.26B | -1.56B | -1.84B | -1.89B | 0 |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -960K | -1.79M | -2.28M | -747K | -4.5M | -4.16M | -5.72M | -6.88M | -5.73M | 0 |
| Minority Interest | 19.27M | 19.27M | 19.27M | 19.27M | 19.27M | 19.97M | 19.97M | 41.97M | 41.97M | 34.51M |
FGEN Cash Flow Statement
FibroGen, Inc. (FGEN) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 7.11M | -66.51M | -76.14M | -78.7M | 81.6M | -82.23M | -145.93M | -315.02M | -138M | -138M |
| Operating CF Margin % | 3.96% | -52.93% | -35.76% | -30.68% | 46.28% | -34.95% | -103.69% | -673.08% | -465.88% | - |
| Operating CF Growth % | 138.27% | -1035.75% | -14.48% | -3.36% | 203.68% | -200.77% | -77.46% | -115.87% | 56.19% | 248.05% |
| Net Income | -58.07M | -120.88M | -86.42M | -76.97M | -189.29M | -290.02M | -293.65M | -284.23M | -47.58M | 215.65M |
| Depreciation & Amortization | 6.04M | 6.1M | 6.56M | 21.45M | 22.05M | 14.81M | 10.6M | 9.93M | 2.69M | 1.09M |
| Stock-Based Compensation | 32.13M | 37.54M | 52.14M | 66.27M | 72.72M | 71.16M | 65.6M | 50.77M | 25.21M | 4.9M |
| Deferred Taxes | -211K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.69M | 1.71M | -30K | -3.8M | 1.5M | 61.74M | 1.09M | 28.2M | -868K | 171.19M |
| Working Capital Changes | 24.52M | 9.02M | -48.4M | -85.66M | 174.63M | 60.08M | 70.43M | -119.69M | -117.46M | -195.97M |
| Change in Receivables | 4.96M | 2M | -55.23M | 35.23M | -11.97M | 25.18M | 765K | 3.43M | -6.74M | 6.77M |
| Change in Inventory | 0 | 0 | 0 | -6.89M | -9.18M | -14.16M | -11M | -1.7M | 22.28M | 9.75M |
| Change in Payables | -298K | -714K | 3.63M | -3.05M | 17.73M | 805K | 5.91M | -15.51M | 14.51M | -3.09M |
| Cash from Investing | 6.62M | 69.87M | -522.12M | 120.02M | 452.49M | -426.97M | 89.12M | 153.66M | 125.99M | 88.85M |
| Capital Expenditures | -1.25M | -8.5M | -8.02M | -5.76M | -3.99M | -5.19M | -3.74M | -2.52M | -266K | -179K |
| CapEx % of Revenue | 0.7% | 6.76% | 3.77% | 2.25% | 2.27% | 2.2% | 2.66% | 5.38% | 0.9% | - |
| Acquisitions | 0 | 0 | 0 | 0 | -2.83M | 0 | 0 | 656K | 1.05M | 90.41M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 5K | 184K | 7K | 0 | -25M | -34.99M | 0 | 0 | 0 |
| Cash from Financing | 6.74M | 496.47M | 13.88M | -4.3M | 13.34M | -563K | 46.78M | 122.75M | -255K | -86.01M |
| Debt Issued (Net) | -403K | -403K | -360K | -12.33M | -13.02M | -5.89M | -538K | 73.59M | -40K | -80.56M |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 139K | -26K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.23M | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -49K |
| Other Financing | -2.74M | -9.24M | -15.61M | -12.75M | -11.46M | -7.37M | 43.13M | 748K | 1.88M | -5.42M |
| Net Change in Cash | 20.46M▲ 0% | 499.88M▲ 2343.4% | -584.4M▼ 216.9% | 37.01M▲ 106.3% | 552.13M▲ 1391.9% | -507.17M▼ 191.9% | -15.52M▲ 96.9% | -42.01M▼ 170.6% | -11.51M▲ 72.6% | 83.45M▲ 0% |
| Free Cash Flow | 5.86M▲ 0% | -75.01M▼ 1381.0% | -84.16M▼ 12.2% | -84.47M▼ 0.4% | 77.61M▲ 191.9% | -112.42M▼ 244.9% | -184.67M▼ 64.3% | -317.54M▼ 71.9% | -138.26M▲ 56.5% | -17.09M▲ 0% |
| FCF Margin % | 3.26% | -59.69% | -39.52% | -32.92% | 44.02% | -47.77% | -131.22% | -678.46% | -466.78% | - |
| FCF Growth % | 128.5% | -1380.96% | -12.2% | -0.36% | 191.88% | -244.85% | -64.27% | -71.95% | 56.46% | 86.46% |
| FCF per Share | 0.09 | -1.03 | -1.00 | -0.97 | 0.86 | -1.22 | -1.97 | -3.26 | -1.38 | -1.38 |
| FCF Conversion (FCF/Net Income) | -0.12x | 0.53x | 0.88x | 1.02x | -0.43x | 0.28x | 0.50x | 1.11x | 2.90x | -0.08x |
| Interest Paid | 295K | 255K | 218K | 174K | 135K | 94K | 104K | 54K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
FGEN Key Ratios
FibroGen, Inc. (FGEN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -33.17% | -33.32% | -15.56% | -14.47% | -38.76% | -86.5% | -258.01% | - | - | 1233.37% |
| Return on Invested Capital (ROIC) | -33.64% | -174.77% | -23.95% | -13.43% | -109.09% | -137.3% | -499.96% | - | - | 75.83% |
| Gross Margin | -4.25% | -56.38% | -10.74% | 99.55% | 94.97% | -90.89% | 85.59% | 91.53% | 47.47% | 82.74% |
| Net Margin | -34.35% | -100.43% | -40.58% | -30% | -107.36% | -123.25% | -208.66% | -607.29% | -160.63% | -182.61% |
| Debt / Equity | 0.56x | 0.17x | 0.18x | 0.10x | 0.09x | 0.44x | - | - | - | 1.11x |
| Interest Coverage | -5.00x | -12.63x | -7.89x | -31.05x | -79.88x | -268.40x | -209.05x | -39.87x | -18.24x | -20.28x |
| FCF Conversion | -0.12x | 0.53x | 0.88x | 1.02x | -0.43x | 0.28x | 0.50x | 1.11x | 2.90x | -0.08x |
| Revenue Growth | -0.69% | -30.02% | 69.46% | 20.48% | -31.28% | 33.46% | -40.19% | -66.74% | -36.71% | -218.29% |
FGEN SEC Filings & Documents
FibroGen, Inc. (FGEN) SEC filings — annual & quarterly reports (10-K, 10-Q)
FGEN Frequently Asked Questions
FibroGen, Inc. (FGEN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
FibroGen, Inc. (FGEN) reported $-118.1M in revenue for fiscal year 2024. This represents a 279% decrease from $65.9M in 2012.
FibroGen, Inc. (FGEN) saw revenue decline by 36.7% over the past year.
Yes, FibroGen, Inc. (FGEN) is profitable, generating $215.7M in net income for fiscal year 2024 (-160.6% net margin).
Dividend & Returns
Yes, FibroGen, Inc. (FGEN) pays a dividend with a yield of 0.30%. This makes it attractive for income-focused investors.
FibroGen, Inc. (FGEN) had negative free cash flow of $17.1M in fiscal year 2024, likely due to heavy capital investments.
Explore More FGEN
FibroGen, Inc. (FGEN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates